Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
Blood|January 17, 2020
Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 studyDavid J Straus, Monika Długosz-Danecka, Sergey Alekseev, et al.
The Lancet. Haematology|May 28, 2021
Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trialDavid J Straus, Monika Długosz-Danecka, Joseph M Connors, et al.
Anticancer Research|July 5, 2020
Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational StudyBartosz Pula, Elzbieta Iskierka-Jazdzewska, Monika Dlugosz-Danecka, et al.
Leukemia & Lymphoma|October 30, 2019
Early induction intensification with cladribine, cytarabine, and mitoxantrone (CLAM) in AML patients treated with the DAC induction regimen: a prospective, non-randomized, phase II study of the Polish Adult Leukemia Group (PALG)Agnieszka Pluta, Tadeusz Robak, Kamil Brzozowski, et al.
Blood|August 24, 2017
HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodiesMalgorzata Bobrowicz, Michal Dwojak, Beata Pyrzynska, et al.
The New England Journal of Medicine|December 12, 2017
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's LymphomaJoseph M Connors, Wojciech Jurczak, David J Straus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2021
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent LymphomaNathan H Fowler, Felipe Samaniego, Wojciech Jurczak, et al.
Blood Advances|August 22, 2025
Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Follicular Lymphoma: Phase 1/2 BRUIN StudyNirav N Shah, Pier Luigi Zinzani, Michael L Wang, et al.
Leukemia Research|May 28, 2014
Case-adjusted bortezomib-based strategy in routine therapy of relapsed/refractory multiple myeloma shown to be highly effective--a report by Polish Myeloma Study GroupAdam Walter-Croneck, Norbert Grzasko, Maria Soroka-Wojtaszko, et al.
Blood Advances|January 16, 2026
Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Marginal Zone Lymphoma: Phase 1/2 BRUIN StudyKrish Patel, Julie M Vose, Sunita D Nasta, et al.
Pageof 7